Showing 4131-4140 of 4164 results for "".
- Novartis Launches App to Collect Patient Data in Studies for Ophthalmic Diseaseshttps://modernod.com/news/novartis-launches-app-to-collect-patient-data-in-studies-for-ophthalmic-diseases/2480209/Novartis announced the launch of its FocalView app, an ophthalmic digital research platform that aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routin
- MeiraGTx Announces AAV-RPGR Granted Fast Track Designation by FDA for Treatment of X-Linked Retinitis Pigmentosa Due to RPGR Deficiencyhttps://modernod.com/news/meiragtx-announces-aav-rpgr-granted-fast-track-designation-by-fda-for-treatment-of-x-linked-retinitis-pigmentosa-due-to-rpgr-deficiency/2480212/MeiraGTx Limited, a clinical stage gene therapy company, announced that the FDA has granted Fast Track designation for AAV-RPGR for the treatment of X-linked retinitis pigmentosa (XLRP) due to defects in the retinitis pigmentosa GTPase regulator (RPGR) gene. “XLRP is a devastating c
- Omeros: Omidria Demonstrates Benefits Across Traditional and Femtosecond Laser-Assisted Cataract Surgery and in IFIS Caseshttps://modernod.com/news/omeros-omidria-demonstrates-benefits-across-traditional-and-femtosecond-laser-assisted-cataract-surgery-and-in-ifis-cases/2480226/Omeros announced that the results of four real-world clinical studies evaluating the benefits of Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual
- Telemedicine Useful in Detecting Retinopathy of Prematurityhttps://modernod.com/news/telemedicine-useful-in-detecting-retinopathy-of-prematurity/2480230/Telemedicine has similar accuracy to ophthalmoscopy in detecting clinically significant retinopathy of prematurity (ROP), researchers say, according to a report in Reuters Health. “ROP is a leading cause of childhood blindness in the U.S. and throughout the world, yet it is often dif
- Omeros Announces Upcoming Presentations of New Data on Omidria at the ASCRS Meetinghttps://modernod.com/news/omeros-announces-upcoming-presentations-of-new-data-on-omidria-at-the-ascrs-meeting/2480246/Omeros announced that the results of four studies directed to the benefits of Omidria across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Congress in Washington, D.C., April 13-17, 2018. The
- Kodiak Reboots Tarcocimab Tedromer Development Program Following Strong Positive Phase 3 DR Resultshttps://modernod.com/news/kodiak-reboots-tarcocimab-tedromer-development-program-following-strong-positive-phase-3-diabetic-retinopathy-results/2481948/Three months after deciding to discontinue tarcocimab tedromer due to two failed late-stage trials, Kodiak Sciences announced it is rebooting its clinical program after its phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to sev
- Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in DME Following Interim Analysishttps://modernod.com/news/oxurion-announces-the-continuation-of-kalahari-phase-2-part-b-study-in-dme-following-interim-analysis/2481293/Oxurion NV announced that an Independent Data Monitoring Committee (IDMC) completed its planned interim analysis of the KALAHARI phase 2, Part B clinical trial evaluating Oxurion’s novel plasma kallikrein (PKal) candidate, THR
- Dompé Announces First Patient Enrolled in Phase 3 Trial of Cenegermin in Patients With Severe Sjögren's-Related Dry Eye Diseasehttps://modernod.com/news/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with-severe-sjogrens-related-dry-eye-disease/2480630/Dompé announced that the first patient has been enrolled in its phase 3 clinical trial to evaluate the efficacy and safety of cenegermin in patients with severe Sjögren's-related dry eye disease, a primary symptom of Sjögren's. This trial is part of a program th
- Novartis Announces Positive Results From Phase 3 Trials of Beovu in DME, Including Dosing Intervals Up to 16 Weekshttps://modernod.com/news/novartis-announces-positive-results-from-phase-3-trials-of-beovu-in-dme-including-dosing-intervals-up-to-16-weeks/2479452/Novartis announced positive results from two phase 3 clinical trials assessing Beovu (brolucizumab) 6 mg versus aflibercept 2 mg in patients with diabetic macular edema (DME). Year 2 of the pivotal KITE trial evaluated Beovu on up to 16-week dosing intervals, and the 1-year KINGFISHER study evalu
- New Ocular Telehealth Program Enables Diabetic Retinopathy Screeninghttps://modernod.com/news/new-ocular-telehealth-program-enables-diabetic-retinopathy-screening/2482241/Visionix USA and 20/20NOW have launched an ocular telehealth program to enable diabetic retinopathy screening. The new technology will be presented at the American Telemedicine Association (ATA)’s 2024 Nexus Conference and Expo in Arizona in May. Visionix and 20/20NOW will be offe